INA-PROACTIVE is a multicenter, prospective, observational cohort study of HIV positive antiretroviral-naĂŻve and treatment-experienced individuals. No investigational treatment or intervention will be used by this study. All participants will be managed according to the Indonesian HIV/AIDS Treatment Guideline and the Standard of Care (SoC) in local clinical setting, with the addition of rapid HIV viral load, CD4 cell count and syphilis testing.
Data will be collected on all participants at baseline and follow up visits every 6 months (±3-month window period). Additional follow up data may be collected on selected participants who meet additional study follow up criteria.
In this report, the focus is on analyzing pediatric patients. Initially, there were 189 pediatric patients under consideration. However, after careful evaluation, six pediatric patients were excluded from the analysis. These exclusions were based on the presence of certain risk factors associated with acquiring HIV, including engaging in heterosexual or homosexual behaviors, being recipients of blood products, or lacking documentation of LOG 700. These criteria were applied to ensure a more homogeneous study population for accurate analysis and interpretation of the data.
Those patients are:| ID_patients | Reason |
|---|---|
| 1045601008 | Blood product recipient |
| 1045701004 | Homosexual |
| 1046301006 | Homosexual |
| 1046801001 | Heterosexual |
| 1046901004 | Heterosexual |
| 1046701001 | Does not have LOG 700 |
In this section, table characteristics is shown for subject characteristics at Enrollment PROACTIVE study.
deskriptif <- read_excel("table_deskriptif.xlsx", na = "-")
options(knitr.kable.NA = '')
deskriptif %>%
kbl() %>%
kable_classic_2(full_width = F)
| Characteristics | Subject (N = 189) |
|---|---|
| Age (months), median (IQR) | 95.0 (63.0 - 147.0) |
| Gender | |
| Male | 90 (47.6%) |
| Female | 99 (52.4%) |
| Risk factors for acquiring HIV | |
| Heteroseksual | 2 (1.1%) |
| Homoseksual | 2 (1.1%) |
| Perinatal | 175 (92.6%) |
| Suspected perinatal | 9 (4.8%) |
| Transplant recipient | 1 (0.5%) |
| Smoking and Alcohol | |
| Ever smoke | 3 (1.6%) |
| Ever consume alcohol | 1 (0.5%) |
| Family Medical History | |
| HIV-Spouse | 1 (53.8%) |
| HIV-Father | 110 (59,1%) |
| HIV-Mother | 173 (93.0%) |
| HIV-Child | 0 (0.0%) |
| HIV-Sibling | 19 (10.2%) |
| HIV-From Household | 1 (0.5%) |
| HIV-Others | 0 (0.0%) |
| TB-Spouse | 0 (0.0%) |
| TB-Father | 38 (24.0%) |
| TB-Mother | 34 (21.5%) |
| TB-Child | 0 (0.0%) |
| TB-Sibling | 8 (5.0%) |
| TB-From Household | 8 (5.0%) |
| TB-Others | 0 (0.0%) |
| Hepatitis B-Spouse | 0 (0.0%) |
| Hepatitis B-Father | 3 (2.1%) |
| Hepatitis B-Mother | 3 (2.1%) |
| Hepatitis B-Child | 0 (0.0%) |
| Hepatitis B-Sibling | 0 (0.0%) |
| Hepatitis B-From Household | 1 (0.7%) |
| Hepatitis B-Others | 0 (0.0%) |
| Hepatitis C-Spouse | 0 (0.0%) |
| Hepatitis C-Father | 6 (4,2%) |
| Hepatitis C-Mother | 1 (0.7%) |
| Hepatitis C-Child | 0 (0.0%) |
| Hepatitis C-Sibling | 0 (0.0%) |
| Hepatitis C-From Household | 0 (0.0%) |
| Hepatitis C-Others | 0 (0.0%) |
| HIV Testing History | |
| Ever tested HIV | 1 (0.5%) |
| Own Initiative tested | 11 (5.8%) |
| Provider Initiated | 171 (90.5%) |
| Others | 7 (3.7%) |
| CD4 and Viral Load | |
| CD4 at baseline | 481.0 (159.5 - 981.5) |
| Latest viral load | 56 (1 - 46000) |
| Highest viral load | 87200 (144 - 712000) |
| Pulmonary and extra-pulmonary tuberculosis prior to and at enrollment | |
| Pulmonary | 71 (37.5%) |
| Others | 106 (56.1%) |
| Extra-Pulmonary | 12 (6.4%) |
| Limfadenitis | 2 (3.7%) |
| Pleural effusion | 3 (1.1%) |
| Bone TB | 5 (0.5%) |
| Other (TB Milier, Skin) | 2 (1.1%) |
| Delivery methods (vaginam, elective and non-elective SC) | |
| Vaginam | 133 (70.4%) |
| Elective Caesarean Section | 22 (11.6%) |
| Non-elective Caesarean Section | 17 (8.9%) |
| Others | 9 (4.7%) |
| Birth history | |
| Birth weight (gram) | 3000 (2800 - 3500) |
| Birth defects | 1 (0.5%) |
| ARV during pregnancy | 2 (1.1%) |
| Child receive ARV | 69 (36.5%) |
| Exclusive breastfeeding | 134 (70.9%) |
| Neonatal status | |
| Full-term | 165 (87.3%) |
| Pre-term | 7 (3.7) |
| Vital Signs | |
| Weight | 13.1 (8.7 - 19.7) |
| Height | 20.1 (22.4 - 16.5) |
| Waist circumference | 55.0 (50.0 - 60.0) |
| Syphilis result | 70 (37.0%) |
deskriptif2 <- read_excel("table_clinical.xlsx")
options(knitr.kable.NA = '')
deskriptif2 %>%
kbl() %>%
kable_classic_2(full_width = F)
| Group | ARV Group | (N,%) | P-value |
|---|---|---|---|
| Alive | NaĂŻve | 7 (4.5%) | 0.5664 |
| < 6 months | 12 (7.7%) | ||
| 6 - 12 months | 10 (6.5%) | ||
| > 12 months | 126 (81.3%) | ||
| LTFU | NaĂŻve | 1 (5.9%) | 0.416 |
| < 6 months | 0 (0.0%) | ||
| 6 - 12 months | 0 (0.0%) | ||
| > 12 months | 16 (94.1%) |
Naive_experience <- read_excel("Naive_experience.xlsx")
ggplot(Naive_experience, aes(x=Var1, y=Freq, fill=Var1)) +
geom_bar(stat = "identity") +
theme_minimal() +
ggtitle("Naive, Experience Group") +
xlab("Groups") +
scale_x_discrete(labels=c("0" = "Naive", "1" = "<6 months",
"2" = "6-12 months", "3"=">12months")) +
geom_text(aes(label = Freq), vjust = -0.3, size = 3.5) +
scale_fill_manual(name = "", labels = c("Naive", "<6 months", "6-12 months",">12months"),
values = c("#22A884FF","#7AD151FF","#FDE725FF", "#440154FF"))
## Warning: Removed 4 rows containing missing values (`position_stack()`).
## Removed 4 rows containing missing values (`position_stack()`).
Survival analysis was conducted among individuals categorized into four groups based on the duration of antiretroviral therapy (ART) treatment: naive, <6 months, 6 to 12 months, and >12 months.
fit1 <- survfit(surv_object ~ Categories, data = Surv_ENR)
summary(fit1)
## Call: survfit(formula = surv_object ~ Categories, data = Surv_ENR)
##
## Categories=1
## time n.risk n.event survival std.err lower 95% CI upper 95% CI
##
## Categories=2
## time n.risk n.event survival std.err lower 95% CI
## 819.0000 13.0000 1.0000 0.9231 0.0739 0.7890
## upper 95% CI
## 1.0000
##
## Categories=3
## time n.risk n.event survival std.err lower 95% CI upper 95% CI
##
## Categories=4
## time n.risk n.event survival std.err lower 95% CI upper 95% CI
## 43 151 1 0.993 0.0066 0.981 1.000
## 274 150 1 0.987 0.0093 0.969 1.000
## 383 149 1 0.980 0.0114 0.958 1.000
## 392 148 1 0.974 0.0131 0.948 0.999
## 518 146 1 0.967 0.0146 0.939 0.996
## 552 145 1 0.960 0.0159 0.929 0.992
## 567 144 1 0.954 0.0172 0.920 0.988
## 708 143 1 0.947 0.0183 0.912 0.983
ggsurvplot(fit1, data = Surv_ENR, pval = TRUE)
By convention, vertical lines indicate censored data, their corresponding x values the time at which censoring occurred.
The log-rank p-value of 0.77 indicates a non-significant result if consider p < 0.05 to indicate statistical significance. In this study, none of the duration of ART treatment were significantly superior, although Categories 1(Naive) and Categories 3(6-12 months) are doing better until end of study.
Surv_ENR$SEX_E1_C2 <- factor(Surv_ENR$SEX_E1_C2 ,
levels = c("1", "2"),
labels = c("Male", "Female"))
fit2 <- survfit(surv_object ~ SEX_E1_C2, data = Surv_ENR)
summary(fit2)
## Call: survfit(formula = surv_object ~ SEX_E1_C2, data = Surv_ENR)
##
## SEX_E1_C2=Male
## time n.risk n.event survival std.err lower 95% CI upper 95% CI
## 383 87 1 0.989 0.0114 0.966 1.000
## 392 86 1 0.977 0.0161 0.946 1.000
## 518 84 1 0.965 0.0196 0.928 1.000
## 552 83 1 0.954 0.0226 0.910 0.999
## 708 82 1 0.942 0.0251 0.894 0.993
##
## SEX_E1_C2=Female
## time n.risk n.event survival std.err lower 95% CI upper 95% CI
## 43 96 1 0.990 0.0104 0.969 1.000
## 274 94 1 0.979 0.0147 0.951 1.000
## 567 93 1 0.969 0.0179 0.934 1.000
## 819 92 1 0.958 0.0206 0.919 0.999
ggsurvplot(fit2, data = Surv_ENR, pval = TRUE)
Similar to the previous plot, which did not indicate statistical
significance, the current plot also shows a non-significant log-rank
p-value of 0.63. This suggests that there are no significant differences
in survival between males and females in this study.
# Fit a Cox proportional hazards model
fit.coxph <- coxph(surv_object ~ Categories + SEX_E1_C2,
data = Surv_ENR)
ggforest(fit.coxph, data = Surv_ENR)
Hazard ratio of 0.73 for sex groups tells that female patients have a reduced risk of dying compared to male patients (which served as a reference to calculate the hazard ratio). Using this model, tells that group of duration ART treatment and sex group does not significantly influence the patients’ risk of death in this study.